Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Michael R Haupts, Ute Essner & Mathias Mäurer. (2024) Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative Disease Management 14:1, pages 11-20.
Read now
Read now
Alyssa M Volmrich, Lauren M Cuénant, Irman Forghani, Sharon L Hsieh & Lauren T Shapiro. (2022) ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy. The Application of Clinical Genetics 15, pages 111-123.
Read now
Read now
Armando Creta, Luana Gilio, Diego Centonze & Roberta Fantozzi. (2022) Usability of an Application Device for Nabiximols Oromucosal Spray in Patients With Upper Limb Impaired Multiple Sclerosis. Neurodegenerative Disease Management 12:4, pages 195-201.
Read now
Read now
Francisco Javier Carod-Artal, Peyman Adjamian, Carlos Vila Silván, Makarand Bagul & Claudio Gasperini. (2022) A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Review of Neurotherapeutics 22:6, pages 499-511.
Read now
Read now
Andrew Chan & Carlos Vila Silván. (2022) Evidence-based Management of Multiple Sclerosis Spasticity With Nabiximols Oromucosal Spray in Clinical Practice: A 10-year Recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Read now
Read now
José María Prieto González & Carlos Vila Silván. (2021) Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials. Expert Review of Neurotherapeutics 21:7, pages 755-778.
Read now
Read now
Friedemann Paul & Carlos Vila Silván. (2021) Effect of Nabiximols On Goal Attainment Scale Scores in Patients With treatment-resistant Multiple Sclerosis Spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Read now
Read now
Michael A Überall. (2020) A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Journal of Pain Research 13, pages 399-410.
Read now
Read now
Sven G Meuth, Thomas Henze, Ute Essner, Christiane Trompke & Carlos Vila Silván. (2020) Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. International Journal of Neuroscience 130:12, pages 1199-1205.
Read now
Read now
Yara Dadalti Fragoso, Adriana Carra & Miguel Angel Macias. (2020) Cannabis and multiple sclerosis. Expert Review of Neurotherapeutics 20:8, pages 849-854.
Read now
Read now
Kodye L. Abbott, Patrick C. Flannery, Kristina S. Gill, Dawn M. Boothe, Muralikrishnan Dhanasekaran, Sridhar Mani & Satyanarayana R. Pondugula. (2020) Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews 52:1, pages 44-65.
Read now
Read now
Jolana Marková. (2019) Newest Evidence for Tetrahydrocannabinol:cannabidiol Oromucosal Spray From Randomized Clinical Trials. Neurodegenerative Disease Management 9:sup2, pages 9-13.
Read now
Read now
Articles from other publishers (71)
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, Messias Gonzaga Pereira & Norberto Cysne Coimbra. (2024) Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders. Basic & Clinical Pharmacology & Toxicology 134:5, pages 574-601.
Crossref
Crossref
Óscar Fernández Fernández, Lucienne Costa-Frossard, Maria Luisa Martínez Ginés, Paloma Montero Escribano, José María Prieto González, Lluís Ramió-Torrentà, Yolanda Aladro, Ana Alonso Torres, Elena Álvarez Rodríguez, Andrés Labiano-Fontcuberta, Lamberto Landete Pascual, Ambrosio Miralles Martínez, Ester Moral Torres & Pedro Oliva-Nacarino. (2024) Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis. Frontiers in Neurology 15.
Crossref
Crossref
Teresa Greco, Elizabeth M. Poole, Amy C. Young & Jessica K. Alexander. (2024) Application of the Bayesian network theory in clinical trial data: Severity shift in spasticity numeric rating scale in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 83, pages 105466.
Crossref
Crossref
Haydee Goicochea Briceño, Yolanda Higueras, Irene Ruiz Pérez, José Manuel García Domínguez, Juan Pablo Cuello, Ariana Meldaña Rivera & María Luisa Martínez Ginés. (2024) Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain. Frontiers in Neurology 15.
Crossref
Crossref
Roua A. Nouh, Ahmed Kamal, Oluwaseyi Oyewole, Walaa A. Abbas, Bishoy Abib, Abdelrouf Omar, Somaia T. Mansour & Anwar Abdelnaser. (2024) Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine. Pharmaceutics 16:2, pages 241.
Crossref
Crossref
Ute Hidding, Tina Mainka & Carsten Buhmann. (2023) Therapeutic use of medical Cannabis in neurological diseases: a clinical update. Journal of Neural Transmission 131:2, pages 117-126.
Crossref
Crossref
Haron M. Jeddi, Jason W. Busse, Behnam Sadeghirad, Mitchell Levine, Michael J. Zoratti, Li Wang, Atefeh Noori, Rachel J. Couban & Jean-Eric Tarride. (2024) Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open 14:1, pages e068182.
Crossref
Crossref
Dénes Kleiner, István László Horváth, Stefania Bunduc, Dorottya Gergő, Katalin LugosiPéter Fehérvári, Péter Hegyi & Dezső Csupor. (2023) Nabiximols is Efficient as Add-On Treatment for Patients with Multiple
Sclerosis Spasticity Refractory to Standard Treatment: A Systematic
Review and Meta-Analysis of Randomised Clinical Trials. Current Neuropharmacology 21:12, pages 2505-2515.
Crossref
Crossref
Victor Voicu, Felix-Mircea Brehar, Corneliu Toader, Razvan-Adrian Covache-Busuioc, Antonio Daniel Corlatescu, Andrei Bordeianu, Horia Petre Costin, Bogdan-Gabriel Bratu, Luca-Andrei Glavan & Alexandru Vlad Ciurea. (2023) Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy. Biomolecules 13:9, pages 1388.
Crossref
Crossref
Carmen Martinez-PazEmilio García-Cabrera & Ángel Vilches-Arenas. (2023) Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review. Cannabis and Cannabinoid Research 8:4, pages 580-588.
Crossref
Crossref
Mohamed Y. Abdelgaied, Mostafa K. Abd El-Aziz, Nada Sherif Amin & Hend M. El Tayebi. (2023) What's your cup of tea? The role of herbal compounds in the management of multiple sclerosis. Multiple Sclerosis and Related Disorders 76, pages 104799.
Crossref
Crossref
Graziella Filippini, Silvia Minozzi, Francesca Borrelli, Michela Cinquini & Kerry Dwan. (2023) Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies. Current Physical Medicine and Rehabilitation Reports 11:3, pages 303-312.
Crossref
Crossref
Jacqueline Nicholas, Fred Lublin, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse, Daniel Checketts, Sajida Javaid & Joshua R. Steinerman. (2023) Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Multiple Sclerosis and Related Disorders 75, pages 104745.
Crossref
Crossref
Nenad Mitrovic. (2023) Das spastische SyndromSpastic Syndrome. Schmerz Nachrichten 23:2, pages 115-123.
Crossref
Crossref
Bahareh Abd‐Nikfarjam, Amirhossein Dolati‐Somarin, Vafa Baradaran Rahimi & Vahid Reza Askari. (2023) Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases. BioFactors 49:3, pages 560-583.
Crossref
Crossref
Roua A. Nouh, Ahmed Kamal & Anwar Abdelnaser. (2023) Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. Pharmaceutics 15:4, pages 1151.
Crossref
Crossref
Michael Guger, Robert Hatschenberger & Fritz Leutmezer. (2023) Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria. Brain and Behavior 13:4.
Crossref
Crossref
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Saneela Tahseen & Shahid Bashir. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
187
216
.
César Eduardo Fernandes, José Eduardo Lutaif Dolci, Leonardo Sobral Navarro, Marcelo Allevato, Clóvis Francisco Constantino, Rodrigo Pastor Alves Pereira, Carlos Roberto de Mello Rieder, Flávia Torino, Wanderley Marques Bernardo & Antônio Geraldo da Silva. (2023) Cannabis products: medical use. Revista da Associação Médica Brasileira 69:3, pages 358-364.
Crossref
Crossref
Vera Belgers, Jantine G. RöttgeringLinda DouwMartin KleinJohannes C.F. KetPeter M. van de VenThomas WürdingerMyra E. van LindeJohanna M. NiersMarkus WeberMarcel G. Olde RikkertJose Lopez-SendonOscar ArrietaKristina B. SvendsenMarcos H.N. ChagasCarlos M.O. de Almeida, Mathilde C.M. KouwenhovenPhilip C. de Witt Hamer. (2023) Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis. Cannabis and Cannabinoid Research 8:1, pages 41-55.
Crossref
Crossref
Massimiliano Pau, Micaela Porta, Gabriella Spinicci, Jessica Frau, Lorena Lorefice, Giancarlo Coghe & Eleonora Cocco. (2022) Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study. Neurological Sciences 44:2, pages 685-691.
Crossref
Crossref
Mariana Kolesarova, Patrik Simko, Nicol Urbanska & Terezia Kiskova. (2023) Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders. Pharmaceutics 15:1, pages 204.
Crossref
Crossref
Clara Grazia Chisari, Joe Guadagno, Peyman Adjamian, Carlos Vila Silvan, Teresa Greco, Makarand Bagul & Francesco Patti. (2023)
A
post hoc
evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
. Therapeutic Advances in Neurological Disorders 16.
Crossref
Crossref
Xintian Lyu, Sílvia M. Illamola, Susan E. Marino, Ilo E. Leppik, Stephen Dahmer, Paloma Lehfeldt, Jeannine M. Conway, Rory P. Remmel, Kyle Kingsley & Angela K. Birnbaum. (2023) Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends. Current Therapeutic Research 99, pages 100709.
Crossref
Crossref
Jonathan Marsden, Valerie Stevenson & Louise Jarrett. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
497
521
.
Ana Bernal‐Chico, Vanja Tepavcevic, Andrea Manterola, Carmen Utrilla, Carlos Matute & Susana Mato. (2022) Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia 71:1, pages 103-126.
Crossref
Crossref
Igor Dykukha, Ute Essner, Herbert Schreiber, Lina Marie Raithel & Iris-Katharina Penner. (2022) Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 68, pages 104173.
Crossref
Crossref
Ivona Maria Tudorancea, Mitică Ciorpac, Gabriela Dumitrița Stanciu, Cătălin Caratașu, Alina Săcărescu, Bogdan Ignat, Alexandra Burlui, Elena Rezuș, Ioana Creangă, Teodora Alexa-Stratulat, Ionuț Tudorancea & Bogdan Ionel Tamba. (2022) The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases. Biomedicines 10:10, pages 2492.
Crossref
Crossref
Francesco Patti, Clara Grazia Chisari, Óscar Fernández, Jorge Sarroca, Elena Ferrer‐Picón, Francisco Hernández Vicente & Carlos Vila Silván. (2022) A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’. European Journal of Neurology 29:9, pages 2744-2753.
Crossref
Crossref
D. Scuteri, F. Guida, S. Boccella, L. Luongo, S. Maione, P. Tonin, P. Nicotera, G. Bagetta & M.T. Corasaniti. (2022) NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol. Biomedicine & Pharmacotherapy 153, pages 113488.
Crossref
Crossref
Ainhoa Bilbao & Rainer Spanagel. (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine 20:1.
Crossref
Crossref
Muhammad Yousaf, Dennis Chang, Yang Liu, Tianqing Liu & Xian Zhou. (2022) Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders. Molecules 27:15, pages 4961.
Crossref
Crossref
Rebecca Spain. (2022) Approach to Symptom Management in Multiple Sclerosis With a Focus on Wellness. CONTINUUM: Lifelong Learning in Neurology 28:4, pages 1052-1082.
Crossref
Crossref
Katia Pane, Serena Boccella, Francesca Guida, Monica Franzese, Sabatino Maione & Marco Salvatore. (2022) Role of gut microbiota in neuropathy and neuropathic pain states: A systematic preclinical review. Neurobiology of Disease 170, pages 105773.
Crossref
Crossref
Rainer Ehling, Barbara Seebacher, Andrea Harsányi, Nicole Ganzbiller, Stephanie Papez, Bernhard Haider, Doris Hoertenhuber, Gottfried Kranz, Roland Tarasiewicz, Josef Spatt, Hermann Moser, Wolfhard Klein, Cosmas Barth, Wolfgang Kubik, Eva Kronberger, Andreas Winkler & Christian Brenneis. (2022) Successful long‐term management of spasticity in people with multiple sclerosis using a software application: Results from a randomized, controlled, multicenter study. European Journal of Neurology 29:6, pages 1697-1707.
Crossref
Crossref
Hina Khan, Fareeha Khalid Ghori, Uzma Ghani, Aneela Javed & Saadia Zahid. (2022) Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis. Molecular Biology Reports 49:6, pages 5117-5131.
Crossref
Crossref
Jose-Manuel Quintero, German Pulido, Luis-Fernando Giraldo, Marta-Ximena Leon, Luis-Eduardo Diaz & Rosa-Helena Bustos. (2022) A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation. Plants 11:10, pages 1357.
Crossref
Crossref
Fatma Haddad, Ghadeer Dokmak & Rafik Karaman. (2022) The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms. Life 12:5, pages 682.
Crossref
Crossref
Yuma T. Ortiz, Lance R. McMahon & Jenny L. Wilkerson. (2022) Medicinal Cannabis and Central Nervous System Disorders. Frontiers in Pharmacology 13.
Crossref
Crossref
Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch & Veronica Popescu. (2021) Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurology 21:1.
Crossref
Crossref
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González & Lluís Ramió-Torrentà. (2021) Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. Frontiers in Neurology 12.
Crossref
Crossref
Jason W Busse, Patrick Vankrunkelsven, Linan Zeng, Anja Fog Heen, Arnaud Merglen, Fiona Campbell, Lars-Petter Granan, Bert Aertgeerts, Rachelle Buchbinder, Matteo Coen, David Juurlink, Caroline Samer, Reed A C Siemieniuk, Nimisha Kumar, Lynn Cooper, John Brown, Lyubov Lytvyn, Dena Zeraatkar, Li Wang, Gordon H Guyatt, Per O Vandvik & Thomas Agoritsas. (2021) Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ, pages n2040.
Crossref
Crossref
Li Wang, Patrick J Hong, Curtis May, Yasir Rehman, Yvgeniy Oparin, Chris J Hong, Brian Y Hong, Mahmood AminiLari, Lucas Gallo, Alka Kaushal, Samantha Craigie, Rachel J Couban, Elena Kum, Harsha Shanthanna, Ira Price, Suneel Upadhye, Mark A Ware, Fiona Campbell, Rachelle Buchbinder, Thomas Agoritsas & Jason W Busse. (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ, pages n1034.
Crossref
Crossref
Emma Fisher, R. Andrew Moore, Alexandra E. Fogarty, David P. Finn, Nanna B. Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S.C. Rice, Michael Rowbotham, Mark Wallace & Christopher Eccleston. (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162:1, pages S45-S66.
Crossref
Crossref
Jenny L. Wilkerson, Joshua A. Bilbrey, Jasmine S. Felix, Alexandros Makriyannis & Lance R. McMahon. (2021) Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior 206, pages 173192.
Crossref
Crossref
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, Anabel Estévez-Carrillo & Juan M. Ramos-Goñi. (2021) Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. The European Journal of Health Economics 22:5, pages 711-721.
Crossref
Crossref
Rajib Dutta. (2021) Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature. Journal of Neuroscience and Neurological Disorders 5:1, pages 034-047.
Crossref
Crossref
Daniel Joseph & Johannes Schulze. (2021) Cannabinoid Activity—Is There a Causal Connection to Spasmolysis in Clinical Studies?. Biomolecules 11:6, pages 826.
Crossref
Crossref
Paolo De Blasiis, Maria Francesca Siani, Allegra Fullin, Mario Sansone, Mariarosa Anna Beatrice Melone, Simone Sampaolo, Elisabetta Signoriello & Giacomo Lus. (2021) Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.. Multiple Sclerosis and Related Disorders 51, pages 102805.
Crossref
Crossref
Hannah L. Pellkofer & Tania Kümpfel. (2021) Schmerzen bei multipler Sklerose und Neuromyelitis-optica-Spektrum-ErkrankungenPain in multiple sclerosis and neuromyelitis optica spectrum disorders. Der Schmerz 35:3, pages 211-222.
Crossref
Crossref
Igor Dykukha, Rolf Malessa, Ute Essner & Michael A Überall. (2021) Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Medicine 22:4, pages 861-874.
Crossref
Crossref
Latha Velayudhan, Katie McGoohan & Sagnik Bhattacharyya. (2021) Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLOS Medicine 18:3, pages e1003524.
Crossref
Crossref
Carmen Navarrete, Adela García-Martín, Alain Rolland, Jim DeMesa & Eduardo Muñoz. (2021) Cannabidiol and Other Cannabinoids in Demyelinating Diseases. International Journal of Molecular Sciences 22:6, pages 2992.
Crossref
Crossref
Ferhat Yenilmez, Odette Fründt, Ute Hidding & Carsten Buhmann. (2021) Cannabis in Parkinson’s Disease: The Patients’ View. Journal of Parkinson's Disease 11:1, pages 309-321.
Crossref
Crossref
Éamon Jones & Styliani Vlachou. (2020) A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules 25:21, pages 4930.
Crossref
Crossref
Clara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, Roberto Bergamaschi, Assunta Bianco, Simona Bonavita, Vincenzo Brescia Morra, Roberto Bruno Bossio, Elisabetta Capello, Letizia Castelli, Paola Cavalla, Gianfranco Costantino, Diego Centonze, Salvatore Cottone, Maura Chiara Danni, Federica Esposito, Alberto Gajofatto, Claudio Gasperini, Angelica Guareschi, Roberta Lanzillo, Giacomo Lus, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Marco Rovaris, Edoardo Sessa, Gabriella Spinicci, Daniele Spitaleri, Paola Valentino, Mauro Zaffaroni, Mario Zappia & Francesco Patti. (2020) Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery & Psychiatry 91:9, pages 914-920.
Crossref
Crossref
Charlie Fairhurst, Ram Kumar, Daniel Checketts, Bola Tayo & Susie Turner. (2020) Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Developmental Medicine & Child Neurology 62:9, pages 1031-1039.
Crossref
Crossref
Ivan Urits, Kyle Gress, Karina Charipova, Kelly Habib, David Lee, Christopher Lee, Jai Won Jung, Hisham Kassem, Elyse Cornett, Antonella Paladini, Giustino Varrassi, Alan D. Kaye & Omar Viswanath. (2020) Use of cannabidiol (CBD) for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology 34:3, pages 463-477.
Crossref
Crossref
Patrícia Alves, Cristina Amaral, Natércia Teixeira & Georgina Correia-da-Silva. (2020) Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. Pharmacological Research 157, pages 104822.
Crossref
Crossref
Giulia Di Stefano, Gianfranco De Stefano, Andrea Di Lionardo, Giorgio Cruccu & Andrea Truini. (2020) Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis. CNS Drugs 34:7, pages 749-761.
Crossref
Crossref
Antonio Carotenuto, Teresa Costabile, Mario De Lucia, Marcello Moccia, Fabrizia Falco, Martina Petruzzo, Marcello De Angelis, Cinzia Valeria Russo, Francesco Saccà, Roberta Lanzillo & Vincenzo Brescia Morra. (2020) Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. Journal of Neurology 267:6, pages 1737-1743.
Crossref
Crossref
Zaid H. Maayah, Shingo Takahara, Mourad Ferdaoussi & Jason R. B. Dyck. (2020) The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis. Inflammation Research 69:6, pages 549-558.
Crossref
Crossref
Kent A. Owusu, Lina Saliba, Abdalla A. Ammar, Mahmoud A. Ammar & Jeffrey Mucksavage. (2020) Application of Cannabinoids in Neurosciences. Critical Care Nursing Quarterly 43:2, pages 216-231.
Crossref
Crossref
Mohammed M. Mohiuddin, Glenio B. Mizubuti, Simon Haroutounian, Shannon M. Smith, Andrew S.C. Rice, Fiona Campbell, Rex Park & Ian Gilron. (2020) Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain. The Clinical Journal of Pain 36:4, pages 302-319.
Crossref
Crossref
Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto & Lluis Ramió. (2020) The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms. Frontiers in Neurology 11.
Crossref
Crossref
F. Block. (2020) Cannabis in der NeurologieCannabis in neurology. DGNeurologie 3:2, pages 116-119.
Crossref
Crossref
Katarzyna Ziętal, Ilona Joniec-Maciejak & Dagmara Mirowska-Guzel. (2020) Current state of knowledge on the use of medical marijuana in some neurological diseases. Pharmacotherapy in Psychiatry and Neurology 36:3, pages 205-225.
Crossref
Crossref
Herman Johal, Christopher Vannabouathong, Yaping Chang, Meng Zhu & Mohit Bhandari. (2020) Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2093796.
Crossref
Crossref
Luigia Cristino, Tiziana Bisogno & Vincenzo Di Marzo. (2019) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology 16:1, pages 9-29.
Crossref
Crossref
Zinah Zamil Al-Ghezi, Philip Brandon Busbee, Hasan Alghetaa, Prakash S. Nagarkatti & Mitzi Nagarkatti. (2019) Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain, Behavior, and Immunity 82, pages 25-35.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref